Sildenafil Plus Hypothermia to Treat Neonatal Encephalopathy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

January 31, 2028

Conditions
Hypoxic-Ischemic Encephalopathy
Interventions
DRUG

Sildenafil Citrate (IV)

Controlled hypothermia initiated before 6h after birth (servo-controlled 33.5°C during 72h followed by a 12-h rewarming period up to 36.5°C), open-label IV Sildenafil Citrate (Revatio®, 10 mg/12.5 mL, Pfizer) 0.4 mg/kg delivered over 3 hours, followed by a maintenance infusion at 1.6 mg/kg/day for 72h

Trial Locations (1)

75005

Unité de Recherche Clinique, Entrepôts de données et Pharmacologie GHU Paris Centre, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER